A Study on Minimal Hepatic Encephalopathy in Cirrhotics. by Vinoth Kumar, R
“A STUDY ON MINIMAL HEPATIC 
ENCEPHALOPATHY IN CIRRHOTICS”  
 
 
DISSERTATION SUBMITTED FOR  
DM MEDICAL GASTROENTEROLOGY 
 
 
BRANCH- IV 
AUGUST 2013 
 
 
 
THE TAMILNADU DR.M.G.R. MEDICAL  
UNIVERSITY CHENNAI,  
TAMILNADU 
 
 
CERTIFICATE 
 
This is to certify that this dissertation entitled “A Study on 
Minimal Hepatic Encephalopathy in Cirrhotics” submitted by Dr. 
R.VINOTH KUMAR to the faculty of Medical Gastroenterology, The 
Tamilnadu Dr.MGR Medical University, Guindy, Chennai-600032, in 
partial fulfilment of the requirement for the award of DM Degree, Branch 
IV (Medical Gastroenterology) is a bonafide work carried out by him 
under my direct supervision and guidance. 
 
 
Prof.Dr.S.Jeevan Kumar,M.D.,D.M  
 
Professor and HOD, 
Department of Digestive Health and 
Diseases, 
Govt.PeripheralHospital, Annanagar,  
Attached to KilpaukMedicalCollege, 
Chennai.   
 Dr.Ramakrishnan, MD., DLO 
 
Dean, 
KilpaukMedicalCollege, 
Chennai 
 
 
 
 
  
 
 
    
  
 
 
 
 
 
 
 
A STUDY ON MINIMAL HEPATIC 
ENCEPHALOPATHY IN CIRRHOTICS 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
I am greatly indebted to my guide Dr.S.Jeevan Kumar, M.D., 
D.M., Professor of Medical Gastroenterology, Department of Digestive 
Health and Diseases, Govt. Kilpauk Medical College, Chennai, for giving 
a chance to undertake this dissertation work under his guidance. Also I 
express my deep sense of gratitude for his encouragement, directions, 
periodical discussions and precious suggestions for shaping my 
dissertation. I also thank him for giving me the permission to do this 
dissertation work in Govt. Peripheral Hospital, Anna Nagar, Chennai-
102. 
I express my gratitude to Dr.P.Ganesh, M.D., D.M., Associate 
Professor, Department of Digestive Health and Diseases, Govt. Kilpauk 
Medical College, for his kind encouragement and review of my work, 
besides providing me with all the required facilities. 
I also thankDr.T.PugazhendhiM.D.,D.M.,Professor of Medical 
Gastroenterology,Govt. Rajiv Gandhi General Hospital,Chennai for his 
constant encouragement and suggestions for my study. 
 
I am extremely grateful to Dr.P.Ramakrishnan,M.D.,D.L.O,Dean, 
Govt. Kilpauk Medical College for granting me the permission to do this 
dissertation in Kilpauk Medical College, Chennai 
I am extremely thankful to Dr.R.Balamurali, M.D.,D.M., 
Dr.G.Ramkumar,D.M. Dr.S.Chitra,M.D.,D.M. and Dr.K.Muthukumaran, 
M.D., D.M.,  Assistant Professors in the Department of Digestive Health 
and Diseases, who have guided me a lot. 
I am also thankful to my colleagues Dr.A.SenthilVadivu M.D.,  
Dr. G. Sathya M.D., Dr.Jayakumarjayakrishnan M.D., Dr.R.Poppy 
Rejoice M.D.,  Dr.A.R.Akilandeswari  M.D., Dr.S.Mukundan M.D., 
Dr.V.Anand M.D., Dr.P.Thirumal M.D.,  Dr.SanthiSelvi M.D.,  
Dr.Tarakeshwari M.D., Dr.BabuVinish M.D.,Dr.VishnuAbishek 
M.D.,Dr.Balaji, M.D.,Dr.Sukumar.D., Dr.SajeethManikanda Prabhu 
M.D.,Dr.Vaishnavi M.D. who have helped me a lot in this dissertation 
work. 
I am extremely thankful to my father Mr. K. Ramachandran, for 
his constant moral support. I also thank my mom Mrs. T.S. Usha, my 
wife Dr. Sumitha and other family members for their constant 
encouragement. I also thank my son Jaivanth Arjun for allowing me to 
complete this dissertation on time. 
I also thank all the referring institutions and doctors for their trust 
and timely referral of needy patients to our department. I thank all the 
patients who have ungrudgingly lent themselves to undergo this study, 
without which this study would have not been possible. 
I am extremely thankful to Dr.Ravanan,Ph.D., Associate 
professor, Department of statistics, Presidency college, Chennai -5  for 
his help in the statistical analysis of my dissertation work. 
I also thank all the paramedical staff of Govt. Peripheral Hospital, 
Anna Nagar for their help. 
 
 
 
 
 
 
 
 
 
CONTENTS 
 
SL.NO. TITLE PAGE 
NO. 
1.  INTRODUCTION 1 
2.  REVIEW OF LITERATURE 3 
3.  AIM OF THE STUDY 34 
4.  MATERIALS AND METHODS 35 
5.  RESULTS AND STATISTICAL 
ANALYSIS 
37 
6.  DISCUSSION 49 
7.  CONCLUSION 53 
8.  BIBLIOGRAPHY  
 ANNEXURES  
 PROFORMA   
 MASTER CHART  
 ETHICAL COMMITTEE APPROVAL 
LETTER 
 
 
  
 
                                                                                                                                                          1 
 
 
 
INTRODUCTION 
Hepatic encephalopathy includes a spectrum of transient and reversible 
neurological and psychiatric manifestations usually found in patients with 
chronic liver disease and portal hypertension. Its occurrence indicates a poor 
prognostic factor with a projected one year survival rate of 43%. It occurs in 
50% to 70% of cirrhotic patients.  The least severe form of hepatic 
encephalopathy, which is not recognized on clinical examination is Minimal 
hepatic encephalopathy (MHE).  It impairs health related quality of life 
(HRQOL). It can be detected by using sensitive tests like number connection 
tests, line tracing tests and figure connection tests, EEG, visual, auditory and 
somatosensory evoked potentials.  Ammonia levels are found to be elevated in 
patients with minimal hepatic encephalopathy and therefore can play a role in 
the causation of minimal hepatic encephalopathy. Minimal hepatic 
encephalopathy has a subtle but negative impact on a patient’s spatial and 
motor skills, the ability to perform complex tasks such as driving, and even 
quality of life. Some studies have reported that patients with MHE can progress 
and later on develop overt hepatic encephalopathy. Due to its negative impact 
on daily living, it has been suggested that the failure to diagnose this condition 
could be classified as a medical error. 
Helicobacter pylori, a gram negative microaerophilic bacteria produces 
ammonia from urea, which is absorbed in the gastric lumen into 
circulation.Infection with these bacteria can result in hyperammonemia and 
hepatic encephalopathy and eradication of these bacteria results in decreased 
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ammonia levels. However the association of Helicobacter pylori in the 
causation of minimal hepatic encephalopathy was not studied in detail. 
We conducted this study in our department to find out the incidence of 
minimal hepatic encephalopathy in patients with cirrhosis and to establish a 
correlation between H.pylori infection in patients with minimal hepatic 
encephalopathy. 
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REVIEW OF LITERATURE 
Hepatic encephalopathy (HE) represents a continuum of transient and 
reversible neurologic and psychiatric abnormalities, varying from subtle altered 
mental status to deep coma. It is a reversible state of impaired cognitive 
function or altered consciousness in patients with liver disease. HE is not a 
single clinical entity. (1) It may reflect reversible metabolic encephalopathy, 
brain atrophy, brain edema, or a combination of these factors. Bajaj and 
collegues in 2011 presented a data in European association for the study of 
liver which showed that deficits in psychomotor speed, working memory, 
response inhibition and attention increase with the severity and number of 
episodes of overt hepatic encephalopathy. 
Hippocrates initially described the neurologic syndromes associated 
with chronic liver disease whereas Adams and Foley published a series of 
papers in mid twentieth century on hepatic encephalopathy. (2) 
Nomenclature 
Hepatic Encephalopathy Consensus Group in 1998 at the World 
Congress of Gastroenterology meeting in Vienna standardized the definitions 
of the different syndromes in Hepatic encephalopathy. Initially hepatic 
encephalopathy and portosystemic encephalopathy were interchangeably 
used.(3) But later the term portosystemic encephalopathy was discarded as it is 
very rare in the absence of intrinsic liver disease. Hepatic encephalopathy 
wasclassified into three main categories. Type A is associated with acute liver 
failure, Type B (B for bypass) is associated with portosystemic shunts without 
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intrinsic liver disease, and Type C is associated with chronic liver failure or 
cirrhosis. Type A HE, formerly known as alfa HE, is remarkably different from 
type B and type C. 
 
 
 
Episodic HE is characterized by changes in the mental state that vary in 
severity and duration. These episodes can be either secondary to a known 
precipitating factor, otherwise called precipitated HE, or can occur in the 
absence of any recognized precipitating factor, and are called spontaneous HE. 
Recurrent HE is defined as that which occurs twice or more in 1 year. 
Persistent HE is defined as the presence of cognitive impairment at baseline 
(lasting beyond 2 weeks) secondary to liver diseasethat negatively impacts on 
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social and occupational functioning. The other term that perished during this 
time of terminology metamorphosis was “subclinical hepatic encephalopathy” (4) 
Instead, the term “minimal hepatic cencephalopathy” was introduced. 
This is defined as HE occurring in patients with liver disease who have 
completely normal mental status and neurologic examination but who have 
cognitive deficits in specific neuropsychometrictests . It is seen in a large 
proportion of cirrhotic subjects and has received a lot of attention by hepatic 
encephalopathy researchers over the last decade. 
Classification and semiquantification of the severity of overt HE was 
developed by Harold Conn in the 1970s and is well known as the WestHaven 
criteria.(5) The following table  illustrates the modified West Haven criteria 
along with the operative definition, which was proposed by Amodio et al.(6) 
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MODIFIED WEST HAVEN CRITERIA 
 
 
The term “covert HE” was introduced, which encompasses minimal HE 
and stage I HE. Covert HE is diagnosed mainly by neuropsychiatric tests as 
most patients in stage I HE will have very subtle signs of mental status 
changes. 
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Minimal hepatic encephalopathy 
Minimal Hepatic encephalopathy may be defined as the presence of 
measurable cognitive defects in patients with liver disease and/ or portal 
systemic shunting, that are not identified by detailed clinical history and 
complete neurological examination, including interview of close family 
members, but are detected by abnormalities in neuropsychometric or neuro 
physiological tests that can be performed at the bedside and in the outpatient 
setting, in the absence of other known causes of abnormal cognitive tests.(7) 
The true incidence of Minimal hepatic encephalopathy in cirrhotics is 
unknown. It ranges from 22 – 74% according to various studies.(8) The different 
incidence  rates for MHE reported in various studies may be due to usage of 
different diagnostic criteria. Defining the cut offs for these neuropsychological 
tests on the basis of age and education can reduce these variations.  Patients 
with advanced liver disease have high prevalance of MHE.Etiology of cirrhosis 
doesn’t affect the prevalence rates of Minimal hepatic encephalopathy.  
Health related quality of life (HRQOL) 
Effect on MHE on daily functioning: 
Patients with minimal hepatic encephalopathy have cognition 
impairment which may have a deleterious effect in quality of life.(9) Complex 
activities like driving, planning are affected whereas  basic activities are 
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preserved.  Multiple studies have shown that the daily functioning of MHE 
patients was affected in a significant manner.  Treatment with lactulose 
improved both cognitive functions and HRQOL(10) 
Effect of MHE on driving 
Schomerus et al and also Watanabe et al demonstrated thatpatients with 
minimal hepatic encephalopathy had impaired driving abilities because of 
deficits in psychomotor function.(11,12) Weinet al also found that patients with 
MHE had a decrease in cognition which leads to impaired driving skills. 
Patients withminimal hepatic encephalopathy had higher rates of traffic rule 
violations as reported by Bajaj et al. A number of studies have shown that 
navigation is needed for safe driving and patients with MHE have impairment 
of this skill which can lead to accidents. Therefore, these studies show MHE 
adversely affects driving skills. 
PATHOGENESIS 
 The exact mechanism of hepatic encephalopathy remains unclear. The 
gut derived toxins are said to play an important role in the pathogenesis of 
hepatic encephalopathy and this concept has emerged from the observation that 
repeated gut lavage leads on to the resolution of hepatic encephalopathy. Overt 
Hepatic encephalopathy has been observed when ammonia containing resins 
are introduced into the gut.(13) 
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Many factors have been implicated in the pathogenesis of hepatic 
encephalopathy.Among the multiple neurotoxins implicated in the pathogenesis 
of hepatic encephalopathy, ammonia is the most well- described neurotoxin 
that is involved. 
Ammonia 
Ammonia is mainly produced in the colon. Colonic bacteria metabolise 
proteins and also other nitrogen based products into ammonia.Ammonia was 
synthesized from glutamine by enterocytes.(14) Ammonia enters the portal 
circulation, and is usually metabolized and cleared by hepatocytes. The reduced 
hepatocyte function in cirrhosis contributes to the increased circulating levels 
of ammonia. Increased arterial ammonia levels were seen in about 90% of 
patients with hepatic encephalopathy. However, these serum levels are neither 
specific nor sensitive for hepatic encephalopathy. 
In the brain, only astrocytes can metabolize ammonia. The enzyme, 
glutamine synthase (responsible for metabolizing ammonia) is present only in 
astrocytes.Astrocytes provide physical and nutritional support for neuronal 
cells and also helps in keeping blood brain barrier intact and thereby regulates 
cerebral blood flow. Lockwood et al demonstrated the uptake of ammonia by 
the neurons in patients with liver disease and hyperammonemia using PET scan 
with N ammonia.(15) Ammonia also has a role in modulating glutamate 
neurotransmission. Neurosteroids were induced by ammonia and it leads to 
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stimulation of GABA-A receptor. Lockwood et al also showed that in patients 
with MHE, increased permeability surface area product causes the ammonia to 
diffuse more freely than normal. Because of this encephalopathy due to 
ammonia can occur inspite of normal ammonia levels.In these patients, 
increased water in the brain was found  by MRI which was demonstrated by 
Cordoba et al.  In these patients, neuropsychological function was well 
correlated with  this finding and it seems to reverses with liver 
transplantation.(16) 
INFLAMMATION 
Inflammation contributes to the pathogenesisand also plays a role in the 
development of overt encephalopathy in patients with MHE .(17) Shawcross et al  
found that the severity of minimal hepatic encephalopathy doesn’t correlate 
with either the severity of liver disease or the blood ammonia levels.(18) This 
study also showed  that  MHE patients had high levels of inflammatory 
markers than patients without MHE. Various cytokines and the standard 
markers of inflammationhave been used in examining the role played by 
inflammationin covert HE.  
This is best illustrated by the induction of hyperammonemia using an 
oral glutamine challenge. Glutamine is rapidly broken down by intestinal 
glutaminaseand leads to a rapid 2–3 fold elevation of blood ammonia levels. 
By using a glutamine oral challenge test along with sensitive psychometric 
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tests, an important phenomenon has been noted. This challenge usually does 
not alter psychometric performance in most patients unless the systemic 
inflammatory markers are also raised. Whether this phenomenon is mediated 
by the blood–brain barrier effects of inflammation or some other mechanism 
remains to be determined.   
The binding of the inflammatory cells or cytokines to cerebral 
endothelial cells allows them  to bypass the normal exclusionary effect of the 
blood–brain barrier.(19)  Whatever be the mechanism, it is imperative to 
definitely identify and treat any infection that may occur as promptly as 
possible in patients with hepatic encephalopathy. 
INTESTINAL FLORA 
Gut flora and endotoxins establish another link between ammonia, 
inflammation and MHE. Varying degrees of intestinal floral imbalance among 
cirrhotic patients was demonstrated by Zhao et al. According to his study, 
increased aerobes and anaerobes are seen but bifidobacterium counts are 
decreased.  Overgrowth of E.coli and staphylococcus species in feces was 
found in MHE patients as reported by Liu et al .(20) Synbiotics can be used to 
treat which causes  increased fecal non urease producing lactobacillus species. 
This change can result in decreased ammonia levels and thereby reversal of 
minimal hepatic encephalopathy. 
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Natural History 
Patients with liver disease are known to have a higher frequency of 
MHE.(21)  MHE can lead to overt encephalopathy, decreased survival and poor 
quality of life. Hence it is mandatory to know whether treatment can induce an 
improvement in these outcomes.  
Many studies such as Hartman et al, Amodio et al and Saxena et found 
that patients with MHE developed overt hepatic encephalopathy much more 
commonly than those patients who did not have minimal hepatic 
encephalopathy.(22) These studies also showed that patients with minimal 
hepatic encephalopathy have an increased risk of mortality when compared 
with patients without minimal hepatic encephalopathy. 
Das et al showed that CTP score of more than 6 (Child class B) in these 
patientshave a higher rate of progression to overt hepatic encephalopathy than 
patients with minimal hepatic encephalopathy and CTP score less than 6.(23) 
Minimal hepatic encephalopathy patients who have  large portosystemic shunts 
and usually have a good prognosis. This shows that the mortality in these 
patients may not be related to minimal hepatic encephalopathy per se, but is 
probably related to the worseningliver function in patients with minimal 
hepatic encephalopathy. 
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Precipitating factors 
The precipitating factors include gastrointestinal bleeding, electrolyte 
imbalance, sepsis, hyponatraemia, hypokalaemia, fluid restriction, excessive 
diuresis,  paracentesis, dehydration,diarrhoea/vomiting, excess protein 
load,constipation,alcohol misuse, CNS - active drugs, TIPS insertion and 
surgery. 
Diagnosis 
PSYCHOMETRIC TESTS  
Psychometric Hepatic Encephalopathy Score 
Several batteries of tests for the diagnosis of HE have been studied, and 
theycenter around detection of deficits in attention and processing speed.(24) 
These tests help to identify impairment in visuo-spatial function, response time 
, attention and inhibition, and they are sensitive to the changes that are 
associated with MHE. The Psychometric Hepatic Encephalopathy Score 
(PHES) was specifically designed to detect these changes associated with 
MHE.  
It comprises 5 different tests: the number connection test A (NCT-A), 
the numberconnection test B (NCT-B), the digit symbol test (DST), the line-
tracing test (LTT), and the serial dotting test (SDT).This score was devised by 
Weissenborn, Schomerus et al. based on the Hamster study.(23) Each of the 
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different  tests looks to identify deficits in different areas: NCT-A and NCT-B 
both evaluate concentration, visuomotor speed and mental tracking, but  NCT-
B does this with greater complexity.  
 
 
 
The DST evaluates the psychomotor and visuomotor speed, while the 
LTT examines visuomotor and visuospatial skills with special attention given 
to speed as well as accuracy. Finally,the SDT is a test of psychomotor 
speed.Ifhowever the PHES is unable to be completed, the Working Group on 
Hepatic Encephalopathyhas recommended that a combination of any 2 of the 
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following 4 tests: NCT-A, NCT-B, DST, or block design test (BDT) is 
necessary to diagnose MHE.  
The recommendation is that any impairment in at least 2 of these 5 
testsby  2 standard deviations beyond age-matched controls (with equal 
education) indicatesdysfunction.(25) The disadvantages of the PHES arethat it 
consumes a lot of time , is often difficult to interpret, a poor test in memory and 
it is not widely available in the United States of America.  
Instead of performing the PHES, Riggio and colleaguesperformed a 
logistical regression analysis. They first incorporated the scores of all the 5 
tests included in the PHES, and then eliminated stepwise the variables that 
could be removed without impairing regression.This was called the Simplified 
Psychometric Hepatic Encephalopathy Score (SPHES).(26) Logistic analysis in 
this study showed that a model that contained only the DST, tSDT, and LTT 
was similar to that containing all the5 tests.This factor helps in simplifying a 
test that is already highly regarded in the diagnosis of MHE. 
 However, SPHES includes the LTT, which requires the longest time to 
score, and there is also a controversy as to how to interpret its two outcomes: 
time taken and errors made. The use of the SPHES decreased the total time 
required for MHE screening but since the NCT-A and B only requirea 
maximum of 3 minutes, the practical utility of this reduction has not yet been 
ascertained. 
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RBANS (Repeatable Battery for Assessment of Neuropsychological Status) 
This is an established battery of tests for the assessment of dementia as 
well as other neurocognitive disorders.(27) This  is a paper and pencil test that 
has  four alternate forms (A, B, C, and D) and takes about 20–30 minutes to 
administer per patient. 
This test has extensive normative databases in the  20–89 years age 
group in the United States of America. Preliminary studies done on patients 
awaiting liver transplantation showed a close correlation between the MELD 
score and performance in RBANS.(28)However the main drawback of this test is 
the remarkable learning effect shown by patients when they are tested at short 
intervals. This feature limits its utility in assessing the response to treatment. 
Computerized psychometric tests 
For the diagnosis of MHE, a variety of computer test batteries have been 
validated over the past few years.(29) Age matched results have been generated. 
These tests are also available online and can be used either for a nominal fee or 
free of charge. This test can be administered in an outpatient setting.  The 
inhibitory control test (ICT) and the cognitive drug research (CDR) tests are the 
most popular testing systems. 
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Inhibitory control tests 
The inhibitory control test (ICT) is a computerized test used to identify 
traumatic injury to the brain and other psychiatric conditions like 
schizophrenia, attention-deficit disorder etc.  It tests the person for attention 
and response inhibition ICT measures in response to lures and targets. The 
reaction times provide an objective measurement of separate but 
complementary aspects of neurological impairment in MHE.  
The lure response is an act of commission and signifies a defect in 
response inhibition.Response inhibition is an essential aspect of executive 
function, which allows a subject to inhibit an incorrect response.Impairment of 
response inhibition is responsible for wrong decisions in psychometric testing 
and also in everyday life. Quantification of these errors in MHE is possible in 
ICT.(30) Bajaj et al. validated this system for minimal HE diagnosis by 
comparing it along with the standard psychometric test (i.e., a paper and pencil 
test).(31) Here, the subject is shown several letters on a computer screen at 500 
ms intervals. The subject is then required to focus mainly on the Xs and the Ys 
that are interspersed between the other letters.  
They are given instructions  to respond (by pressing the space bar) 
wheneveran X is followed by a Y or a Y is followed by an X, (called “target”) 
and also to refrain from responding when X is followed by X or Y is followed 
by Y (called “lure”). The subject has to go through six runs of the above test 
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each lasting 2 minutes in addition to the training run at the beginning. The 
subjects are graded based on their lure response. More than five lures helps 
diagnose minimal HE with 88% sensitivity. 
Cognitive drug research test 
Investigators in Newcastle, UK have validated this testing system in the 
diagnosis of MHE. CDRT is composed of 7 different tests. It is presented on a 
computer screen and patients respond with a “Yes/no” response. These scores 
are reported on a scale of performance in 5 different domains, which include 
continuity of attention, quality of episodic memory power of attention, speed of 
memory and the quality of working memory. But, the major limitation of this 
test is that patients definitely need to undergo a practice session about 1–7 days 
prior to the test. 
Critical flicker fusion frequency test: 
In 2002, Kircheis et al. developed this test for the diagnosis of MHE. 
This neurophysiologic test is based on the principle of hepatic 
retinopathy.(32)The Muller cells in the retina (similar to astrocytes in brain)  are 
thought to undergo  similar changes. This alteration changes the perception of 
light frequency by the retina of the affected person. Here, light pulses are 
shown to the patient, initially at higher frequencies of about 60 Hz, and then 
progressively reducing them by 0.1 Hz/s. At the higher frequencies, the subject 
perceives the light pulses as a single stream of light. Critical frequency is that 
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frequency at which the patient first perceives it as discrete light pulses. A 
critical frequency of <39Hz helps diagnose minimal HE with high sensitivity 
and specificity, and this test positively correlates with the paper and pencil 
psychometric tests. This test can be administered in both inpatient and 
outpatient settings and may take about 15 minutes totally.  
An important prerequisite for optimal performance in this test is 
binocular vision. This test is not influenced by either the education or by 
occupation of the subject and is widely used in therapeutic trials in the 
management of hepatic encephalopathy as it can demonstrate improvement 
without any learning effect. However, limited availability of the test is the main 
reason for it not becoming popular. 
Electroencephalogram 
The major finding on EEG is a decrease in the wave frequency along 
with a general increase in wave amplitude. Initially, theta-waves (frequency  4 
to 7 cps) occur which gradually predominate and are then committed by delta 
waves with a frequency of 1-3 cps. Before termination, there is a loss of wave 
amplitude along with a flattening of the curve. These abnormalities may be also 
be found even in cirrhotic patients without any clinical signs of 
encephalopathy. No relationship was identified between the grade of hepatic 
encephalopathy and the degree of EEG abnormalities. The sensitivity of using 
the EEG for the diagnosis of subclinical HE is very limited compared to the 
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psychometric tests. The EEG is only useful for follow-up examinations, 
predominantly.(33) Evoked potentials are subdivided into 2 groups (exogenous 
and endogenous). The exogenous evoked potentials like the flash or 
checkerboard visual evoked potentials (VEP), brainstem auditory evoked 
potentials (BAEP) and somatosensory evoked potentials are used to examine 
the function of sensory pathways.  
The endogenous evoked potentials are only measures of cognitive 
function. In the only study that has compared the different exogenous evoked 
potentials for their sensitivity in diagnosing hepatic encephalopathy, the BAEP 
was found to be the most sensitive measure for the diagnosis of HE. The most 
sensitive test in evoked responses is p300 peak obtained in an auditory oddball 
paradigm.  These tests can be used to supplement neurological or 
neuropsychiatric examination. Overt encephalopathy develops in cirrhotics 
with abnormal p300 event related potentials than  in patients who don’t have 
any such abnormality. 
Treatment of MHE 
Ammonia plays a main role in the pathogenesis of MHE. Empirical 
therapy is based on the principle of decreasing the production and absorption of 
ammonia in the gut for which many agents have been found beneficial. 
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Nutritional interventions 
The European Society for Parenteral and Enteral Nutrition has 
recommended in 2006, that patients with cirrhosis should eat at least 1.2 g/kg 
of protein daily. It also recommended that the diet in these patients should be 
supplemented with branched-chain amino acids (BCAAs) and vegetable 
protein whenever hepatic encephalopathy has developed. Vegetable-based 
protein has been found to be better tolerated by patients with cirrhosis than the 
meat-based protein. 
Pharmacological therapy 
Non-absorbable disaccharides include lactulose and lactitol. Lactulose 
reduces blood ammonia levels by various mechanisms thereby helps in treating  
MHE. Lactulose should be started at a dose of 30 to 60ml per day. Appropriate 
duration of therapy was not known although some studies recommend to 
uselaculose for 3 to 6 months.  Treatment of MHE with lactulose improves the 
patient’s quality of life and psychometric performance.(34) Kale et al. reported  
that the interstitial brain edema  resolves after treatment for 3 weeks with 
lactulose in  patients with MHE and also noticed  improvement in the 
neuropsychiatric performance.(35) 
 Prasad et al. also reported the effectiveness of lactulose in patients 
with MHE. He reported that following treatment with lactulose for 3 months, 
the psychometric tests which  was abnormal previously were normalized and 
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patients quality of life was also improved. These findings were confirmed by 
another study which compares lactulose, prebiotic and LOLA along with no 
treatment.  Lactulose or lactitolare considered as intestinal probiotics with 
various actions on the gut flora. A meta-analysis ofvarious  randomized trials 
showed lactulose improves quality of life in patients with minimal hepatic 
encephalopathy. Branched-chain amino acids, flumazenil, L–ornithine L–
aspartate, acetyl L-carnitine, and probiotics/synbiotics are also tried in the 
treatment of MHE with varying results. 
Prebiotics, probiotics or synbiotics 
These drugs are useful in treating minimal hepatic encephalopathy and 
can be used over a long period for treating MHE.(36,37) Liu et al. reported  that  
acidifying gut lumen by altering the gut flora  using synbiotics results in 
decrease of  E.coli and staphylococcal species which are urease producing 
organisms and increase in non urease producing organisms thereby causes 
reduction of ammonia levels and reversal of MHE in 50% of patients. A 
randomized trial showed that patients with MHE improved after the 
supplementation of probiotic yogurt which shows probiotics also have a role in 
the treatment of MHE. Several studies reported that probiotics improves the 
patients quality of life.(38) All these drugs reduce the bacterial urease activity 
thereby reducing the production of ammonia.  Additionally,  it also causes 
increased clearance of ammonia by hepatocytes by reducing oxidative stress 
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and inflammation in the hepatocytes. Therefore it is clear that probiotics can be 
used in the treatment of MHE and can be used as an alternative to lactulose. 
L-ornithine–L-aspartate 
The effectiveness of LOLA in the treatment of MHE is not proved. A 
recent study reported that LOLA is as effective as probiotics and lactulose in 
treating MHE. That study also stated that MHE patients after treatment with 
LOLA had better quality of life and normalization of psychometric tests. 
However further studies are needed to confirm the effectiveness of LOLA in 
treating MHE.  
Antibiotics 
The effectiveness of antibiotics in treating MHE is controversial. 
Metronidazole,(40) vancomycin, paramomycin etc., have been reported to 
reverse HE (41). Probably, the major mechanism of action of these antibiotics is 
in the small intestine where bacterial overgrowth has beenreported.Further 
studies are needed with these antibiotics to assess the efficacy in MHE.  
Helicobacter Pylori 
Helicobacter pylori is a gram-negative microaerophilic bacterium 
recognized as the primary etiologic agent for gastric cancer. The H.pylori 
bacterium has been designated as a definite carcinogen by the International 
Agency for Research on Cancer (IARC). 
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Helicobacter pylori are unique bacteria suited to live in the acidic 
environment that is present in the human stomach. The spiral shape of the 
bacterium and multiple unipolar flagella protects the organism from low 
pH.H.pylori produces urease which is responsible for the production of 
ammonia from urea.  They produce large amounts of urease, an enzyme that 
hydrolyzes urea to alkaline ammonia and carbon dioxide.The multiple routes of 
transmission are fecal-oral, oral-oral or gastro-oral route.(42) 
One more source of bacterial transmission is infected gastric secretions. 
Transmission can also occur with improper disinfection of endoscopes and 
accessories.(43) 
H. pylori showsstrict affinity for the gastric mucosa and the intestinal 
epithelium with gastric metaplasia.It does not colonize gastric epithelium with 
intestinal metaplastic change, as the production of antimicrobial factors select 
against colonization. Helicobacter pylori very rarely colonize the deeper parts 
of the gastric glandular mucosa since O-glycans present there impair its 
growth.(44) H.pylori reduces the secretory leukocyte protease inhibitor 
(antibacterial molecule) which could prevent the infection from persistence.  
Most of the ammonia originates from the gut, where it is produced by 
the bacterial flora.  The stomach, when infected with H. pylori is an alternative 
site of ammonia production. In a normal person, the ammonia is extracted by 
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the liver and therefore, in liver failure, large quantities of ammonia reach the 
systemic circulation due to porto-systemic shunting and impaired ureagenesis. 
The causal role of H. pylori as a cause of hyperammonaemiain persons 
with liver cirrhosis has not been fully clarified. The reduction in the blood 
ammonia levels seen after H. pylori eradication in some studies has been 
attributed to the nonspecific effect of antibiotic therapy on the ammonia 
producing gut flora rather than the eradication of H.pylori. 
NONGASTRIC DISEASES AND H.PYLORI INFECTION 
H.pylori infection is associated with a number of diseases like 
scleroderma, acne rosacea, thyroidits, guillianbarre syndrome, raynauds etc.  
Although it is postulated , evidence supporting an association with the above 
mentioned diseases is weak.(45) 
H.Pylori and MHE 
H.pylori causes increased ammonia production.  The role of H.pylori in 
causing minimal hepatic encephalopathy has not been well studied. But some 
studies reported an increased prevalance of H. pylori in patients with MHE and 
that eradication of H. pylori leads to a decrease in the serum ammonia levels. 
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Study showing increased incidence of H.pylori in patients with MHE 
1. Role of Helicobacter Pylori infection in the pathogenesis of MHE and 
 effect of its eradication – AvinashAgarwal, Alok Gupta, Mam 
 Chandra.(46) Indian J Gastroenterol (Jan-Feb2011) 30(1):29-32. 
 
This study shows that  there is a significant association between the 
presence of H.pylori and MHE in cirrhotic patients and anti H.pylori treatment 
resulted in the reduction in blood ammonia levels and also correction of MHE. 
Diagnostic Tests for Helicobacter pylori 
During an endoscopic procedure, 3 methods can be used to identify 
H.pylori.They are the urease test of biopsy specimen, histopathological 
examination and culture.  Urease test of biopsy specimen has been proposed as 
the initial test of choice since the method is quick, relatively inexpensive, 
generally accurate and easy to perform.  
The gastric tissue specimen is tested for urease activity by putting many 
bits of tissue in a medium containing pH reagent and urea. Urease produced by 
H.pylori hydrolyzes urea and liberates ammonia, which produces an alkaline 
pH and this results in a change in colour of the test medium.(47) The test results 
can be read  within a few minutes to hours. This test is less costly than 
histological examination. Therefore, a cost-cutting measure is to delay sending 
tissue for histological examination till urease test results are available. Urease 
tests are 95% to 100% specific with false-positive tests being not very 
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common. Accuracy of the urease test can be affected by the presence of blood 
in the stomach and also recent or current use of drugs such as bismuth-
containing compounds, antibiotics or PPIs. A  negative urease test therefore 
cannot exclude H. pylori infection in an individual taking the above 
medications. Testing biopsy tissues from various regions of the stomach, stop 
offending drug for a few weeks and delayed UGI scopy can improve the 
sensitivity of the test. 
Histopathological examination of the gastric mucosa isn’t necessary for 
the diagnosis of H.pylori. However, this test may provide information about the 
activity of Helicobacter pylori and mucosal inflammation severity. Apart from 
this, histological examination can also detect the presence of metaplasia, 
dysplasia, and neoplasia.Biopsy of “clinically suspicious” areas, multiple 
biopsies, taking samples from both the lesser and greater curvatures of gastric 
antrum as well as the body should be done mainly when searching for atrophic 
gastritis and/or intestinal metaplasia.  Histopathologic exam is said to be the 
gold standard for confirming H.pylori infection. This test has a sensitivity of 
95% and a specificity of 98%.(48)With the use of special stains like giemsa and 
genta, the detection rate is higher(49). 
H.pylori is difficult to culture since the organism is very fastidious, 
grows slowly and requires specialized media and growth environment.The 
tissue obtained for culture should be placed in a container with only few drops 
of saline. Culture is not routinely recommended and indicated only in patients 
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with refractory disease in whom antibiotic sensitivity is needed to start 
subsequent treatment.(50) 
 Nonendoscopic tests are usually used to diagnose H. pylori infection, 
and the most popular method used is serology. IgG antibodies can be detected 
by ELISA to many bacterial antigens. Testing IgA and IgM class antibodies are 
not reliable and are not routinely recommended. The advantage of Serology is 
inexpensive, noninvasive. Serology is ideal for a primary care setting. The 
sensitivity of serology is high which is around 90 to 100%, its specificity varies 
from 76% to 96%.  
The specificity is highly variable in low prevalence areas. In places 
where the infection is uncommon,  the NPV of serology is high while the 
corresponding PPV is poor.Hence, before starting treatment the positive 
serology should be reconfirmed by a second method such as urea breath test or 
stool antigen test.Because of this, some studies suggest to use a test which 
helps to detect active infection initially.   
The eradication of infection is suggested by the conversion of previous 
serological test to a negative one after treatment. But, for many months to years 
the serology remains positive. Because of this serologic scar , it is not used to 
confirm eradication of  H.pylori. Urea breath test detects active H. pylori 
infection. It is also useful in making primary diagnosis, to confirm eradication 
and to confirm the serology.(51) The principle of  Urea breath test is  orally 
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administered urea that is tagged with a carbon isotope, either 13C or 14C is 
hydrolysed by bacteria and  produces ammonia and tagged CO2, which can 
then be detected in breath samples.Since non radioactive isotope is used it can 
safely used for testing pregnant women and children.  
The sensitivity of UBT is 88% to 95% and specificity is more than 95%. 
Patients with antisecretory medications, ppi can have false negative results and 
the accuracy can be improved by stopping the drugs before testing. It is also 
not appropriate in patients with previous gastric resection. 
Another nonendoscopic method used is an immunoassay to detect the 
presence of stool bacterial antigens. This test is used to diagnose active H. 
pylori infection. It is also useful in confirming eradication of H.pylori. The 
sensitivity  is 94% and specificity si 97% which is comparable with urea breath 
test.  
Traditional lab based stool test is accurate than rapid stool antigen test. 
Drugs can affect the sensitivity of the stool antigen test like UBT. Hence 
interfering drugs should be stopped appropriately before testing. 
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TREATMENT 
Various regimens are available for treating H.pylori.  Sequential 
regimen consists of 10 day therapy with a ppi, amoxicillin both given twice a 
day for the first 5 days followed by clarithromycin 500mg and tinidazole 
500mg for the next 5 days. The eradication rates with sequential regimen is 
89% which is higher than the conventional triple therapy. 
It was effective in patients infected with clarithromycin-resistant 
organisms (89% vs. 29%).(52) Multiple studies have confirmed the efficacy  of 
this sequential therapy.Eradication rates are much lower with dual regimens 
and hence they are no longer recommended for treating H.pylori.(53) 
One of the first regimen used to treat H.pylori is Bismuth-based 
regimen. This regimen consists of bismuth subsalicylate, metronidazole, 
tetracycline and a ppi given four times a day for 14 days gives almost 80% 
eradication rate. Because of the large number of tablets, frequent dosing and 
side effects this regiment was not well tolerated and hence it is considered as a 
second line regimen.(54) 
In united states, bismuth, metronidazole and tetracycline are available in 
a single capsule to simplify the bismuth based treatment. In a comparative 
study, patients treated with three of the above capsules four times a day and a 
PPI twice a day in combination for 10 days had comparable eradication of 
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H.pylori with thosepatients treated with traditional PPI triple therapy (88% vs. 
83%).(55) 
Eradication rates of various regimens varies. The eradication rate is 46% 
for ppi dual regimen, 76% for bismuth based regimen, 80% for ranitidine and 
bismuth based regimen and 70% for ppi triple drug regimens.(57) Eradication 
rates are higher when two antibiotics are used instead of one.  
If H.pylori is not eradicated in the previous one or two regimens then, 
rescue therapy is  recommended. In rescue therapy, amoxicillin 1gm, 
levofloxacin 250mg and a ppi is given for 10 days. The eradication rates with 
rescue therapy is 80%.  Rifabutin containing regimen is also used for 
eradication H.pylori infection. In this regimen rifabutin300mg , amoxicillin 1 
gm and a ppi each twice daily is used for 10 days. The eradication rate of this 
regimen is 85%.  
Initially ppi with triple therapy is recommended for eradication of 
H.pylori infection. If clarithromycin resistence is suspected, then patients 
should be started on sequential therapy.(58) Bismuth containing regimen or ppi 
triple regimens can be used for retreatment. 
HelicotecUT – rapid urease test 
 
Helicotec UT is designed to detect the urease activity of Helicobacter 
pylori in gastric mucosal biopsies.  H.pylori produce large amounts of  urease 
 
                                                                                                                                                          32 
 
 
 
which  hydrolyzes  urea into ammonium ion and bicarbonate. When a tissue 
specimen is immersed in the Helicotec UT test gel, the elevated pH level due to 
the presence and activity of urease is indicated by the change in colour of pH 
indicator in the test gel.  
If the gel changes colour from yellow to pink or red, the test is regarded 
as positive whereas if the gel colour remains yellow after 24 hours, then the test 
is considered negative. 
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RAPID UREASE TEST KIT USED IN THIS STUDY- 
 
HelicotecUT® PLUS 
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AIM AND OBJECTIVES OF THE STUDY 
 
 1.  To study the incidence of minimal hepatic encephalopathy in 
 asymptomatic       cirrhotics. 
2.  To study the prevalence of helicobacter pylori in asymptomatic 
 cirrhotics with minimal hepatic encephalopathy. 
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MATERIALS AND METHODS 
This is a hospital based prospective study conducted  in our Department 
of Digestive Health and Diseases(DDHD), Government peripheral hospital, 
Chennai from August  2012 to January 2013   on 50 patients with cirrhosis of 
liver without overt encephalopathy. 
 All patients were subjected to liver function tests, serum 
 creatinine, prothrombin time, Hbsag, Anti Hcv, ultrasound 
 abdomen and gastroscopy.  
 Psychometric tests were done to all patients. 
 Helicobacter pylori testing was done by rapid urease test 
  (helicotec UT, Strong biotech corp, Taiwan). 
 Ethical committee approval was obtained from Kilpauk medical 
  college before starting the study. 
 Written informed consent was obtained from all participating  
  subjects in regional language (Tamil). Privacy was ensured. 
 Statistical analysis was done by statistical analysis software SPSS 
  (version 17.0). 
Psychometric tests 
All study patients underwent 5 psychometric tests.  NCT-A, NCT-B, 
Line tracing, Serial dotting and Digit symbol test were performed in all 
patients. The procedure was briefed to all the patients before the test and the 
patients were given a trial run before the tests.Exact time taken for each test 
was recorded and normative values were obtained from 30 control subjects. 
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Diagnosis of MHE was made when there is significant reduction i.e., > 2 
standard deviations from appropriate normative population in 2 or more tests. 
INCLUSION CRITERIA 
• Patients with cirrhosis without overt hepatic encephalopathy. 
• Age 30 -70 years. 
• Both sexes 
• Patients with cirrhosis of liver in ultrasound and CT    
EXCLUSION CRITERIA 
• Age below 30 years and above 70 years. 
• Patients with overt hepatic encephalopathy (based on  clinical 
examination)  
• Patients with history of recent GI bleed.  
• Patients with neurological illness,  
• Patients with poor vision 
• History of  H. Pylori eradication treatment in previous 3 months. 
• History of any antibiotics intake in the past 2 weeks 
• Patients with severe comorbid illness 
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RESULTS AND STATISTICAL ANALYSIS 
A total of 50 patients were recruited for this study. 
Table 1 shows the cut off values for 30 normal controls. 
Diagnosis of MHE in study group was made when there is significant reduction 
i.e., > 2 standard deviations from control group in 2 or more tests. 
Table 1 : Descriptives for control only  
Descriptive Statistics 
 N 
Minim
um 
Maxim
um Mean 
Std. 
Deviation 
NCT_A 30 30 100 58.20 16.961 
NCT_B 30 55 165 113.67 29.388 
Line tracing 30 55 150 91.57 23.018 
Serial dotting 30 50 105 70.67 17.207 
Digital symbol 30 15 28 20.67 3.680 
Valid N (listwise) 30     
 
Based on the results , 35 (70%) of the 50 patients had minimal hepatic 
encephalopathy. In NCT-A, 35 patients in the study group were abnormal. In 
NCT-B, 34 patients had abnormal results. The abnormal results in line tracing, 
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serial dotting, digital symbol test were 34,37,36 respectively. In our study the 
incidence of MHE in asymptomatic cirrhotics was 70%.   
Overall Positivity 
Crosstab 
  Group 
Total 
 
45 
 
P 
value 
  Control Study 
Overall 
Positivity 
Negat
ive 
Count 30 15   
 
 
 
< .010 
(highly 
signific
ant) 
  % within 
Overall 
Positivity 
66.7% 33.3% 100.0% 
  % within 
Group 100.0% 30.0% 56.3% 
 Positi
ve 
Count 0 35 35 
  % within 
Overall 
Positivity 
.0% 100.0% 100.0% 
  % within 
Group .0% 70.0% 43.8% 
Total Count 30 50 80 
 % within 
Overall 
Positivity 
37.5% 62.5% 100.0% 
 % within 
Group 100.0% 100.0% 100.0% 
Highly significant at 1% level 
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In our study, MHEpatients  had no significant relationship with age, 
Child-Pugh grade and etiology of cirrhosis. 
In our study, male patients had high prevalence of MHE than female 
patients which is statistically significant. 
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Sex * Overall Positivity 
Crosstab 
  Overall Positivity  
Total 
 
 
 
P value 
  Negative Positive 
Sex Male Count 7 27 34  
 
< .010 
(highly 
significan
t 
  % within 
Sex 20.6% 79.4% 100.0% 
  % within 
Overall 
Positivity 
46.7% 77.1% 68.0% 
 Female Count 8 8 16 
  % within 
Sex 50.0% 50.0% 100.0% 
  % within 
Overall 
Positivity 
53.3% 22.9% 32.0% 
Total Count 15 35 50 
 % within 
Sex 30.0% 70.0% 100.0% 
 % within 
Overall 
Positivity 
100.0% 100.0% 100.0% 
 
Highly significant at 1% level 
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Sex
FemaleMale
C
ou
nt
30
20
10
0
Overall Positivi
Positive
Negative
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Etiology * Overall Positivity 
Crosstab 
  
Overall Positivity 
Total Negative Positive 
Etiology Ethanol Count 9 21 30 
% within 
Etiology 30.0% 70.0% 100.0% 
% within Overall 
Positivity 60.0% 60.0% 60.0% 
Hep B Count 4 8 12 
% within 
Etiology 33.3% 66.7% 100.0% 
% within Overall 
Positivity 26.7% 22.9% 24.0% 
Hep C Count 1 3 4 
% within 
Etiology 25.0% 75.0% 100.0% 
% within Overall 
Positivity 6.7% 8.6% 8.0% 
NAFLD Count 0 3 3 
% within 
Etiology .0% 100.0% 100.0% 
% within Overall 
Positivity .0% 8.6% 6.0% 
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 Wilson Count 1 0 1 
% within 
Etiology 100.0% .0% 100.0% 
% within Overall 
Positivity 6.7% .0% 2.0% 
Total Count 15 35 50 
% within 
Etiology 30.0% 70.0% 100.0% 
% within Overall 
Positivity 100.0% 100.0% 100.0% 
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WilsonNAFLDHep CHep BEthanol
C
ou
nt
30
20
10
0
Overall Positiv
Positive
Negative
 
                                                                                                                                                          46 
 
 
 
 
In our study, H. pylori infection was found in 30 patients(60%) out of 50 
patients. In  patients with MHE, 26 patients (74%) had H.pylori  infection, 
whereas only 4 patients (26%) had H.pylori infection in non MHE group which 
is statistically highly significant. 
 
 MHE  - 
POSITIVE 
MHE -  
NEGATIVE 
H.Pylori  - positive 26 4 
H.Pylori  - negative 9 11 
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Rapid urease * Overall Positivity 
Crosstab 
  Overall Positivity Total 
 
 
P value 
  
Nega 
tive 
Positive
Rapid 
urease 
Positive Count 4 26 30  
 
<.010 
(highly 
significant 
  % within 
Rapid 
urease 
13.3% 86.7% 100.0% 
  % within 
Overall 
Positivity 
26.7% 74.3% 60.0% 
 Negativ
e 
Count 11 9 20 
  % within 
Rapid 
urease 
55.0% 45.0% 100.0% 
  % within 
Overall 
Positivity 
73.3% 25.7% 40.0% 
Total Count 15 35 50 
 % within 
Rapid 
urease 
30.0% 70.0% 100.0% 
 % within 
Overall 
Positivity 
100.0% 100.0% 100.0% 
Highly significant at 1% level 
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DISCUSSION 
Minimal hepatic encephalopathy impairs daily function and patient's 
quality of life. Patients with minimal hepatic encephalopathy have difficulties 
with attention, working memory and response inhibition which is associated 
with impairment in driving. Patients with MHE are more prone for motor 
vehicle accidents. Hence, diagnosing and treating MHE is mandatory to avoid 
morbidity and mortality. 
The impact of minimal hepatic encephalopathy on daily life is 
enormous. Several studies that looked at the quality of life in patients with 
minimal hepatic encephalopathy showed  that  patients  with MHE have poor 
quality of life.(59) Schomerus et al also reported that patients with minimal 
hepatic encephalopathy, do not have regular employment compared to patients 
without MHE. 
 In our study the incidence of MHE in asymptomatic cirrhotic patients is 
70%. The incidence of MHE has been reported to vary from 22% to 75% in 
various studies.  Sharma et al reported a incidence rate of 41% in asymptomatic 
cirrhotic patients.(60) . 
Our study has higher incidence rate than this study. The reason for the 
large variation is due to the variability in diagnostic criteria. Defining the cut- 
offs for these neuropsychological tests on the basis of age and education can 
reduce the variations in incidence rates. 
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In our study five tests were performed in all patients. Age matched 
controls were taken and diagnosis of MHE was made if there is more than 2 
standard deviation in results compared to controls in two or more psychometric 
tests.(60) 
Most of the studies done in patients with minimal hepatic 
encephalopathy revealed no sex preponderance. Both males and females are 
equally affected. In a study done by Agarwal et al,(46)  no significant 
relationship was found between males and females whereas in our study male 
patients were more prone for minimal hepatic encephalopathy.  
Out of 34 male patients, 27 patients had minimal hepatic encephalopathy 
which is statistically significant at 5%level. This relationship doesn’t correlate 
well with most of the studies. 
The most common etiology for cirrhosis in our study is ethanol followed 
by hepatitis B and hepatitis C. Most of the studies don't show any relationship 
with etiology and MHE. Our study also doesn’t show any relationship with 
statistical significance. 
In our study, thepresence of MHE had no significant relationship with 
age and CTP score. It is comparable with most studies which also revealed the 
same. 
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Hyperammonemia is the widely studied etiological factor in the 
pathogenesis of hepatic encephalopathy. About 50% of ammonia is produced 
by intestinal bacteria and rest of them from dietary protein and glutamine. 
H.pylori is rich in enzyme urease and produces ammonia from urea.  
Although the amount of  ammonia produced in small, it is postulated in 
the pathogenesis of minimal hepatic encephalopathy.(61) In a study done by 
Avinashagarwal et al, lucknow, patients with MHE had high ammonia levels 
than patients without MHE.  
Moreover patients with MHE and H.pylori infection have high ammonia 
levels than patients with MHE and H.pylori infection. This finding shows a 
possible association between H.pylori and minimal hepatic encephalopathy. 
In our study the prevalance of H.pylori is 60%. The prevalance of 
H.pylori infection is increased in patients with minimal hepatic encephalopathy 
(74%) whereas  the incidence is only 26% in the non MHE group which is 
statistically very significant.   
These results were comparable to a hospital based study done in 
lucknow, uttarpradash by agarwal et al.  In that study H.pylori infection was 
found in 22 of 35 patients with minimal hepatic encephalopathy (63%) whereas 
only 11 patients of 30 patients without MHE had H pylori infection (30%).   
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Most of the studies reported increased prevalence  with raised ammonia 
levels in patients with MHE. Moreover avinash et al also reported a reduction 
in blood ammonia levels and normalization of psychometric tests after 
treatment with anti H.pylori drugs. 
Hence we conclude that prevalence of  H.pylori is higher in patients 
with minimal hepatic encephalopathy and further studies are needed to prove a 
definitive causative role in the pathogenesis of minimal hepatic 
encephalopathy. 
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CONCLUSION 
1. This study shows the high incidence of minimal hepatic encephalopathy 
 in asymptomatic cirrhotic patients. 
 
2. This study proves that the  prevalence of H.pylori is markedly high in 
 patients with minimal hepatic encephalopathy. 
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SEX 
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SOCIO ECONOMIC STATUS 
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CHIEF  COMPLAINTS 
                                                     Abdominal pain 
                                                     Abdominal distension 
Hemetemesis 
                                                     Jaundice 
                                                     Melena 
PAST HISTORY  
                                                    Diabetes Mellitus 
                                                    Hypertension  
                                                    H/O any neurological illness 
                                                Drug History 
PERSONAL HISTORY  
                                                   ALCOHOL/SMOKING 
GENERAL EXAMINATION 
                                                SIGNS OF LIVER CELL FAILURE 
                                                 BP 
                                                 ANAEMIA 
                                                JAUNDICE 
                                                FLAPPING TREMORS 
                                                HEPATOMEGALY  
                                                ASCITES 
                                                PER RECTAL EXAMINATION 
PSYCHOMETRIC TESTS 
  Number Connection Test A  
Number connection Test B 
Line tracing test 
Serial dotting 
Digit symbol test 
INVESTIGATIONS 
TC            DC                   HB%           Motion Occult Blood                 
LIVER FUNCTION TEST              S.Bilirubin         T        D 
                                                      SGOT                     SGPT 
                                                  SAP 
                                                 Serum Proteins 
BLOOD SUGAR                        F                  PP 
VIRAL MARKERS: HBsAg and Anti HCV 
USG ABDOMEN 
 
UPPER G I ENDOSCOPY WITH ANTRAL BIOPSY 
 
RAPID UREASE TEST      
S NO Name Age Sex Etiology NCT_A NCT_B Line tracing Serial dotting Digit symbol Rapid urease CTP
1 Neelakandan 38 m Ethanol 225 sec 360sec 230sec 220sec 9 pos B
2 Suriya 39 f Hep c 70 sec 140 sec 80 sec 60 sec 24 neg A
3 Rathnam 58 f Hep B 55 sec 110 sec 95 sec 75 sec 22 Pos B
4 Dhanasekeran 43 m Ethanol 195 sec 255 sec 165 sec 190 sec 6 pos A
5 Sathyam 46 m Hep B 195 sec 270 sec 250 sec 250 sec 8 pos B
6 Mariammal 52 f Ethanol 75 sec 120 sec 60 sec 115 sec 20 neg A
7 Kuppusamy 55 m Ethanol 310 sec 340 sec 265 sec 175 sec 7 pos B
8 Chandran 58 m Ethanol 70 sec 120sec 75sec 75 sec 22 neg A
9 Hameed 49 m Ethanol 80 sec 135 sec 90 sec 80 sec 17 pos A
10 Vimal 39 m Hep C 210 sec 225 sec 175 sec 195 sec 6 neg B
11 Akilan 58 m Ethanol 190 sec 310 sec 300 sec 165 sec 7 pos A
12 Saravanan 44 m Hep C 255 sec 330 sec 190 sec 250 sec 7 pos B
13 Arun 38 m Hep B 235 sec 265 sec 250 sec 310 sec 4 pos A
14 Subash  36 m NAFLD 190 sec 310 sec 175 sec 230 sec 7 neg B
15 Harichandran 45 m Ethanol 280 sec 315 sec 310 sec 225 sec 8 neg B
16 Kannammal 50 F Hep B 55 sec 100 sec 120 sec 75 sec 20 neg A
17 Fathima 56 F Ethanol 115 sec 220 sec 180 sec 225 sec 8 pos A
18 Ramesh 39 m Ethanol 160 sec 305 sec 250 sec 145 sec 6 pos B
19 kalinga 46 m Ethanol 55 sec 115 sec 80 sec 60 sec 23 neg B
20 Azmal 42 m Hep B 75 sec 255 sec 135 sec 225 sec 12 pos B
21 Pichai 60 m Ethanol 235 sec 255 sec 255 sec 315 sec 10 pos B
22 Sridhar 50 m Hep B 130 sec 250 sec 175 sec 175 sec 7 neg C
23 Mala 45 f Hep B 135 sec 315 sec 115 sec 205 sec 6 pos B
24 Parvathy 46 F Ethanol 55 sec 115 sec 60 sec 75 sec 24 neg A
25 Kasi 52 M Hep B 175 sec 285 sec 225 sec 225 sec 7 pos A
26 Kuppan 60 m Ethanol 240 sec 360 sec 250 sec 300 sec 10 pos A
27 Murali 42 M Ethanol 145 sec 295 sec 250 sec 255 sec 10 neg A
28 Ravi 54 M Ethanol 195 sec 290 sec 190 sec 200 sec 8 neg A
29 Gopal 47 m Ethanol 45 sec 120 sec 70 sec 65 sec 25 neg  A
30 Mani 50 m Ethanol 190 sec 280 sec 215 sec 265 sec 5 pos C
31 Babu 42 m Hep C 250 sec 310 sec 300 sec 250 sec 12 pos B
32 Seker 48 m Ethanol 70 sec 105 sec 55 sec 65 sec 26 neg B
33 Velankanni 42 f Ethanol 200 sec 235 sec 190 sec 255 sec 8 pos B
34 Saraswathy 49 f wilson 65 sec 120 sec 55 sec 65 sec 22 neg A
35 John 36 m Ethanol 60sec 100 sec 60 sec 55 sec 22 neg A
36 Vijayalakshmi 46 f NAFLD 160 sec 250 sec 180 sec 165 sec 10 pos A
37 Joseph 56 m Ethanol 175 sec 235 sec 225 sec 235 sec 8 pos C
38 meiyammai 50 f Hep B 115 sec 235 sec 175 sec 250 sec 7 pos B
39 Selvi 47 F Hep B 80 sec 115 sec 125 sec 85 sec 22 neg B
40 Pramoth kumar 41 m Ethanol 270 sec 350 sec 200 sec 250 sec 5 pos A
41 Raja 42 m Ethanol 215 sec 250 sec 195 sec 135 sec 5 neg B
42 Hussain 52 m Ethanol 250 sec 315 sec 240 sec 180 min 12 pos B
43 kamalam 50 f Ethanol 150 sec 310 sec 250 sec 195 sec 12 pos B
44 Jenas 49 f NAFLD 185 sec 350 sec 170 sec 190 sec 12 pos A
45 Vijayakumar 34 m Hep B 175 sec 280 sec 175 sec 255 sec 5 pos B
46 Karthick 48 m Ethanol 230 sec 255 sec 235 sec 225 sec 13 neg B
47 Mani 47 m Ethanol 270 sec 310 sec 195 sec 165 sec 7 pos A
48 Ramathal 51 f Hep B 180 sec 285 sec 255 sec 160 sec 6 neg B
49 Vimala 47 f Ethanol 85 sec 115 sec 110 sec 85 sec 18 pos B
50 Chidambaram 49 m Ethanol 235 sec 285 sec 310 sec 115 sec 10 pos A
S.NO Name age sex NCT‐A NCT‐B Line tracing serial dotting digit symbol
1 Rajendran 34 m 30 sec 100 sec 82 sec 60 sec 26
2 shankar 37 m 57 sec 165 sec 70 sec 80 sec 20
3 John  56 m 55 sec 150 sec 55 sec 100 sec 23
4 suresh 39 m 55 sec 165 sec 75 sec 60 sec 17
5 balaji 34 m 95 sec 135 sec 130 sec 105 sec 16
6 geetha 38 f 35 sec 80 sec 75 sec 50 sec 26
7 Praveen 32 m 44 sec 105 sec 150 sec 70 sec 24
8 kamaleswar 33 m 45 sec 115 sec 110 sec 75 sec 17
9 priya 32 f 65 sec 80 sec 100 sec 50 sec 25
10 vijayakumar 43 m 45 sec 75 sec 105 sec 65 sec 23
11 munusamy 42 m 40 sec 60 sec 95 sec 50 sec 20
12 madhu 39 m 55 s ec 55 sec 85 sec 90 sec 17
13 dhanasekar 45 m 65 sec 120 sec 80 sec 60 sec 15
14 dhakshinamoo 38 m 65 sec 130 sec 105 sec 65 sec 18
15 jaya 44 f 90 sec 140 sec 115 sec 75 sec 25
16 gopal 48 m 55 sec 115 sec 80 sec 55 sec 21
17 tamilanban 43 m 50 sec 90 sec 85 sec 80 sec 20
18 janani 48 f 60 sec 90 sec 110 sec 85 sec 17
19 rehman 55 m 45 sec 125 sec 115 sec 55 sec 18
20 mariammal 39 f 65 sec 135 sec 120 sec 100 sec 16
21 malliga 46 f 55 sec 110 sec 75 sec 55 sec 27
22 kannan 48 m 60 sec 105 sec 55 sec 65 sec 20
23 sundaram 43 m 45 sec 100 sec 65 sec 50 sec 22
24 abirami 48 f 35 sec 85 sec 75 sec 55 sec 28
25 shahul  53 m 65 sec 120 sec 85 sec 65 sec 19
26 kamalakannan 46 m 55 sec 135 sec 95 sec 75 sec 20
27 murugan 48 m 75 sec 145 sec 105 sec 80 sec 21
28 haribabu 42 m 100 sec 160 sec 115 sec 105 sec 18
29 latha 39 f 60 sec  100 sec 60 sec 55 sec 24
30 arunkumar 52 m 80 sec 120 sec 75 sec 85 sec 17
